1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Bone Disorders Global Clinical Trials Review, H2, 2015

Bone Disorders Global Clinical Trials Review, H2, 2015

  • October 2015
  • -
  • GlobalData
  • -
  • 209 pages

Bone Disorders Global Clinical Trials Review, H2, 2015

Summary

GlobalData's clinical trial report, “Bone Disorders Global Clinical Trials Review, H2, 2015" provides an overview of Bone Disorders clinical trials scenario. This report provides top line data relating to the clinical trials on Bone Disorders. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table Of Contents

Bone Disorders Global Clinical Trials Review, H2, 2015
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Bone Disorders to Musculoskeletal Clinical Trials 15
Clinical Trials by Phase in G7 Countries 17
Clinical Trials in G7 Countries by Trial Status 18
Clinical Trials by E7 Countries: Proportion of Bone Disorders to Musculoskeletal Clinical Trials 19
Clinical Trials by Phase in E7 Countries 21
Clinical Trials in E7 Countries by Trial Status 22
Clinical Trials by Phase 23
In Progress Trials by Phase 24
Clinical Trials by Trial Status 25
Clinical Trials by End Point Status 26
Subjects Recruited Over a Period of Time 27
Clinical Trials by Sponsor Type 28
Prominent Sponsors 29
Top Companies Participating in Bone Disorders Therapeutics Clinical Trials 31
Prominent Drugs 33
Latest Clinical Trials News on Bone Disorders 34
Sep 01, 2015: Viking Therapeutics Initiates Clinical Trial for VK5211, a Selective Androgen Receptor Modulator, for Acute Hip Fracture 34
Clinical Trial Profile Snapshots 35
Appendix 206
Abbreviations 206
Definitions 206
Research Methodology 207
Secondary Research 207
About GlobalData 208
Contact Us 208
Disclaimer 208
Source 209

List of Tables
Bone Disorders Therapeutics, Global, Clinical Trials by Region, 2015* 6
Bone Disorders Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 8
Bone Disorders Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9
Bone Disorders Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2015* 10
Bone Disorders Therapeutics Clinical Trials, Europe, Top Five Countries, 2015* 11
Bone Disorders Therapeutics Clinical Trials, North America, Top Countries, 2015* 12
Bone Disorders Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2015* 13
Bone Disorders Therapeutics Clinical Trials, Central and South America, Top Countries, 2015* 14
Proportion of Bone Disorders to Musculoskeletal Clinical Trials, G7 Countries (%), 2015* 16
Bone Disorders Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 17
Bone Disorders Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 18
Proportion of Bone Disorders to Musculoskeletal Clinical Trials, E7 Countries (%), 2015* 20
Bone Disorders Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 21
Bone Disorders Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 22
Bone Disorders Therapeutics, Global, Clinical Trials by Phase, 2015* 23
Bone Disorders Therapeutics, Global, Clinical Trials In Progress by Phase 2015* 24
Bone Disorders Therapeutics, Global, Clinical Trials by Trial Status, 2015* 25
Bone Disorders Therapeutics Clinical Trials, Global, by End Point Status, 2015* 26
Bone Disorders Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 27
Bone Disorders Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015* 28
Bone Disorders Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 30
Bone Disorders Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 32
Bone Disorders Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 33

List of Figures
Bone Disorders Therapeutics, Global, Clinical Trials by Region (%), 2015* 6
Bone Disorders Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 7
Bone Disorders Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9
Bone Disorders Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2015* 10
Bone Disorders Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2015* 11
Bone Disorders Therapeutics Clinical Trials, North America, Top Countries (%), 2015* 12
Bone Disorders Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2015* 13
Bone Disorders Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2015* 14
Proportion of Bone Disorders to Musculoskeletal Clinical Trials, G7 Countries (%), 2015* 15
Bone Disorders Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 17
Bone Disorders Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 18
Proportion of Bone Disorders to Musculoskeletal Clinical Trials, E7 Countries (%), 2015* 19
Bone Disorders Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 21
Bone Disorders Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 22
Bone Disorders Therapeutics, Global, Clinical Trials by Phase (%), 2015* 23
Bone Disorders Therapeutics, Global, Clinical Trials In Progress by Phase, 2015* 24
Bone Disorders Therapeutics, Global, Clinical Trials by Trial Status, 2015* 25
Bone Disorders Therapeutics Clinical Trials, Global, by End Point Status, 2015* 26
Bone Disorders Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 27
Bone Disorders Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015* 28
Bone Disorders Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 29
Bone Disorders Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 31
Bone Disorders Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 33
GlobalData Methodology 207

Companies Mentioned
Novartis AG
Amgen Inc.
BioMarin Pharmaceutical Inc.
Merck and Co., Inc.
Eli Lilly and Company
Novo A/S
Clementia Pharmaceuticals, Inc.
Bayer AG
Baxter International Inc.
Ablynx NV

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • November 2016
  • by GlobalData

PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025 Summary Schizophrenia is a heterogeneous behavioral and cognitive syndrome involving chronic or recurrent psychosis. The disorde ...

PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • November 2016
  • by GlobalData

PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025 Summary Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung ...

OpportunityAnalyzer: Myelofibrosis - Opportunity Analysis and Forecasts to 2025

OpportunityAnalyzer: Myelofibrosis - Opportunity Analysis and Forecasts to 2025

  • $ 10995
  • Industry report
  • November 2016
  • by GlobalData

OpportunityAnalyzer: Myelofibrosis - Opportunity Analysis and Forecasts to 2025 Summary Myelofibrosis (MF) is a rare blood disorder, which is characterized by bone marrow fibrosis. Currently, there is ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.